Narayana Hrudayalaya Ltd.
NHHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
19 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 19 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220530 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220816 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221114 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230215 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230529 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230811 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231121 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240222 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240531 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240813 | 2024-06-30 | yes | |
| TRANSCRIPT | 20250811 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241111 | 2024-09-30 | yes | |
| TRANSCRIPT | 20251124 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250224 | 2024-12-31 | yes | |
| TRANSCRIPT | 20260224 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250602 | 2025-03-31 | yes | |
| TRANSCRIPT | 20251107 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260602 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260810 | 2026-06-30 | yes |
NH
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,877.70 |
| 52-week range | 1605.3 – 2080.3 |
| Return 1M | -0.66% |
| Return 3M | -4.04% |
| Return 1Y | 9.09% |
| Return 3Y | 76.8% |
| Return 5Y | 260.54% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 2,684.00 |
| Other income | 35.00 |
| Total income | 2,719.00 |
| Cost of materials consumed | 0.00 |
| Purchases of stock-in-trade | 520.00 |
| Changes in inventories | -6.00 |
| Employee benefit expense | 725.00 |
| Finance costs | 87.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.63 | 0.00 |
| institutions foreign | 0.09 | -0.01 |
| institutions domestic | 0.09 | -0.00 |
| mutual funds | 0.07 | 0.00 |
| public | 0.36 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 19 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,142.00 | 1,128.00 | 1,222.00 | 1,233.00 | 1,305.00 | 1,204.00 | 1,279.00 | 1,341.00 | 1,400.00 | 1,367.00 | 1,475.00 | 1,507.00 | 1,644.00 | 2,151.00 | 2,594.00 | 2,684.00 |
| Other income | 31.00 | 12.00 | 15.00 | 15.00 | 18.00 | 18.00 | 24.00 | 23.00 | 24.00 | 18.00 | 27.00 | 24.00 | 24.00 | 23.00 | 29.00 | 35.00 |
| Total income | 1,173.00 | 1,140.00 | 1,236.00 | 1,249.00 | 1,324.00 | 1,222.00 | 1,303.00 | 1,364.00 | 1,424.00 | 1,385.00 | 1,502.00 | 1,531.00 | 1,668.00 | 2,174.00 | 2,623.00 | 2,719.00 |
| Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 268.00 | 243.00 | 256.00 | 275.00 | 284.00 | 259.00 | 294.00 | 282.00 | 317.00 | 270.00 | 305.00 | 305.00 | 323.00 | 407.00 | 525.00 | 520.00 |
| Changes in inventories | -11.00 | -3.00 | 6.00 | -4.00 | 0.00 | -15.00 | -20.00 | 6.00 | -16.00 | 7.00 | -0.00 | 0.00 | -1.00 | -26.00 | -18.00 | -6.00 |
| Employee benefit expense | 217.00 | 220.00 | 227.00 | 245.00 | 255.00 | 254.00 | 249.00 | 276.00 | 282.00 | 277.00 | 275.00 | 296.00 | 299.00 | 459.00 | 749.00 | 725.00 |
| Finance costs | 15.00 | 19.00 | 21.00 | 21.00 | 23.00 | 25.00 | 28.00 | 34.00 | 35.00 | 37.00 | 41.00 | 45.00 | 42.00 | 65.00 | 91.00 | 87.00 |
| Depreciation and amortisation | 49.00 | 57.00 | 56.00 | 59.00 | 55.00 | 63.00 | 65.00 | 62.00 | 65.00 | 70.00 | 82.00 | 84.00 | 87.00 | 122.00 | 154.00 | 156.00 |
| Other expenses | 423.00 | 414.00 | 456.00 | 446.00 | 457.00 | 426.00 | 462.00 | 473.00 | 509.00 | 506.00 | 537.00 | 569.00 | 620.00 | 943.00 | 828.00 | 975.00 |
| Total expenses | 962.00 | 950.00 | 1,023.00 | 1,043.00 | 1,075.00 | 1,013.00 | 1,078.00 | 1,133.00 | 1,192.00 | 1,166.00 | 1,241.00 | 1,300.00 | 1,371.00 | 1,971.00 | 2,329.00 | 2,457.00 |
| Profit before exceptional items and tax | 211.00 | 190.00 | 214.00 | 206.00 | 248.00 | 209.00 | 226.00 | 232.00 | 232.00 | 219.00 | 261.00 | 231.00 | 297.00 | 203.00 | 294.00 | 262.00 |
| Exceptional items | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.00 | 0.00 | 0.00 | -51.00 | -0.00 | 0.00 |
| Profit before tax | 211.00 | 190.00 | 214.00 | 206.00 | 248.00 | 209.00 | 226.00 | 232.00 | 232.00 | 219.00 | 253.00 | 231.00 | 297.00 | 152.00 | 294.00 | 262.00 |
| Current tax | 45.00 | 28.00 | 39.00 | 31.00 | 29.00 | 26.00 | 51.00 | 30.00 | 29.00 | 29.00 | 42.00 | 34.00 | 36.00 | 30.00 | 76.00 | 56.00 |
| Deferred tax | -3.00 | 8.00 | 1.00 | -9.00 | -8.00 | -6.00 | -16.00 | 0.00 | 4.00 | -3.00 | 15.00 | 1.00 | 1.00 | -8.00 | -12.00 | -3.00 |
| Tax expense | 42.00 | 36.00 | 40.00 | 22.00 | 22.00 | 20.00 | 35.00 | 30.00 | 33.00 | 26.00 | 57.00 | 35.00 | 37.00 | 22.00 | 64.00 | 53.00 |
| Profit for the period | 169.00 | 154.00 | 173.00 | 184.00 | 227.00 | 188.00 | 191.00 | 201.00 | 199.00 | 193.00 | 197.00 | 197.00 | 258.00 | 127.00 | 224.00 | 207.00 |
| Profit attributable to owners | 169.00 | 154.00 | 173.00 | 184.00 | 227.00 | 188.00 | 191.00 | 201.00 | 199.00 | 193.00 | 197.00 | 197.00 | 258.00 | 127.00 | 224.00 | 207.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 26.00 | 12.00 | -7.00 | -4.00 | 15.00 | -1.00 | 4.00 | -2.00 | 5.00 | 36.00 | -6.00 | 0.00 | 69.00 | 30.00 | 97.00 | -13.00 |
| Total comprehensive income | 195.00 | 166.00 | 166.00 | 180.00 | 241.00 | 187.00 | 195.00 | 199.00 | 204.00 | 229.00 | 191.00 | 197.00 | 328.00 | 157.00 | 320.00 | 194.00 |
| Earnings per share, basic | 8.31 | 7.57 | 8.53 | 9.06 | 11.16 | 9.26 | 9.39 | 9.92 | 9.78 | 9.50 | 9.71 | 9.68 | 12.72 | 6.24 | 11.02 | 10.20 |
| Earnings per share, diluted | 8.31 | 7.57 | 8.53 | 9.06 | 11.16 | 9.26 | 9.39 | 9.92 | 9.78 | 9.50 | 9.71 | 9.68 | 12.72 | 6.24 | 11.02 | 10.20 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 2,861.00 | 3,128.00 | 2,582.00 | 3,701.00 | 4,525.00 | 5,018.00 | 5,483.00 | 7,896.00 |
| Other income | 17.00 | 24.00 | 28.00 | 35.00 | 65.00 | 75.00 | 92.00 | 100.00 |
| Total income | 2,878.00 | 3,152.00 | 2,611.00 | 3,736.00 | 4,590.00 | 5,093.00 | 5,575.00 | 7,996.00 |
| Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 687.00 | 722.00 | 665.00 | 921.00 | 1,012.00 | 1,112.00 | 1,141.00 | 1,560.00 |
| Changes in inventories | 0.00 | 23.00 | 12.00 | -12.00 | -11.00 | -38.00 | -5.00 | -44.00 |
| Employee benefit expense | 624.00 | 674.00 | 627.00 | 768.00 | 879.00 | 1,004.00 | 1,093.00 | 1,803.00 |
| Finance costs | 71.00 | 85.00 | 76.00 | 66.00 | 69.00 | 97.00 | 146.00 | 244.00 |
| Depreciation and amortisation | 137.00 | 186.00 | 184.00 | 183.00 | 210.00 | 242.00 | 278.00 | 448.00 |
| Other expenses | 1,262.00 | 1,286.00 | 1,095.00 | 1,370.00 | 1,679.00 | 1,788.00 | 1,977.00 | 2,960.00 |
| Total expenses | 2,782.00 | 2,976.00 | 2,660.00 | 3,298.00 | 3,838.00 | 4,205.00 | 4,631.00 | 6,971.00 |
| Profit before exceptional items and tax | 96.00 | 176.00 | -49.00 | 438.00 | 752.00 | 889.00 | 944.00 | 1,025.00 |
| Exceptional items | 0.00 | -11.00 | -7.00 | -9.00 | -0.00 | 0.00 | -8.00 | -51.00 |
| Profit before tax | 96.00 | 165.00 | -56.00 | 430.00 | 752.00 | 889.00 | 936.00 | 974.00 |
| Current tax | 0.00 | 41.00 | 0.00 | 50.00 | 140.00 | 138.00 | 130.00 | 177.00 |
| Deferred tax | 34.00 | 1.00 | -42.00 | 38.00 | 5.00 | -39.00 | 16.00 | -18.00 |
| Tax expense | 34.00 | 42.00 | -42.00 | 88.00 | 145.00 | 99.00 | 146.00 | 158.00 |
| Profit for the period | 59.00 | 119.00 | -14.00 | 342.00 | 607.00 | 790.00 | 791.00 | 806.00 |
| Profit attributable to owners | 59.00 | 119.00 | -14.00 | 342.00 | 606.00 | 789.00 | 790.00 | 806.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | -0.00 | 5.00 | -2.00 | 26.00 | 57.00 | 14.00 | 34.00 | 197.00 |
| Total comprehensive income | 59.00 | 124.00 | -16.00 | 368.00 | 663.00 | 803.00 | 824.00 | 1,003.00 |
| Earnings per share, basic | 2.92 | 5.86 | -0.70 | 16.85 | 29.85 | 38.86 | 38.90 | 39.67 |
| Earnings per share, diluted | 2.92 | 5.86 | -0.70 | 16.84 | 29.85 | 38.86 | 38.90 | 39.67 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 3,725.00 | 4,162.00 | 4,787.00 | 5,625.00 | 6,243.00 | 7,265.00 | 7,742.00 | 12,474.00 |
| Non-current assets | 2,657.00 | 2,868.00 | 3,111.00 | 3,679.00 | 4,196.00 | 4,715.00 | 4,948.00 | 8,542.00 |
| Current assets | 1,069.00 | 1,294.00 | 1,676.00 | 1,946.00 | 2,047.00 | 2,502.00 | 2,794.00 | 3,932.00 |
| Property, plant and equipment | 1,834.00 | 1,923.00 | 2,075.00 | 2,198.00 | 2,616.00 | 3,814.00 | 3,947.00 | 4,527.00 |
| Capital work-in-progress | 121.00 | 259.00 | 365.00 | 514.00 | 737.00 | 70.00 | 135.00 | 267.00 |
| Goodwill | 58.00 | 117.00 | 118.00 | 118.00 | 118.00 | 119.00 | 120.00 | 1,391.00 |
| Other intangible assets | 40.00 | 166.00 | 148.00 | 133.00 | 125.00 | 108.00 | 93.00 | 1,033.00 |
| Inventories | 73.00 | 72.00 | 75.00 | 110.00 | 120.00 | 110.00 | 111.00 | 155.00 |
| Trade receivables | 386.00 | 432.00 | 556.00 | 422.00 | 543.00 | 555.00 | 586.00 | 656.00 |
| Cash and cash equivalents | 279.00 | 155.00 | 112.00 | 264.00 | 246.00 | 457.00 | 414.00 | 770.00 |
| Total equity and liabilities | 3,725.00 | 4,162.00 | 4,787.00 | 5,625.00 | 6,243.00 | 7,265.00 | 7,742.00 | 12,474.00 |
| Equity | 1,801.00 | 2,132.00 | 2,503.00 | 2,885.00 | 3,207.00 | 3,628.00 | 4,062.00 | 4,540.00 |
| Equity share capital | 204.00 | 204.00 | 204.00 | 204.00 | 204.00 | 204.00 | 204.00 | 204.00 |
| Other equity | 1,596.00 | 1,927.00 | 2,297.00 | 2,679.00 | 3,001.00 | 3,422.00 | 3,855.00 | 4,333.00 |
| Total liabilities | 1,925.00 | 2,030.00 | 2,284.00 | 2,739.00 | 3,036.00 | 3,637.00 | 3,680.00 | 7,935.00 |
| Non-current liabilities | 975.00 | 1,042.00 | 1,202.00 | 1,629.00 | 1,711.00 | 2,444.00 | 2,378.00 | 6,108.00 |
| Current liabilities | 950.00 | 987.00 | 1,082.00 | 1,110.00 | 1,324.00 | 1,146.00 | 1,247.00 | 1,827.00 |
| Borrowings, non-current | 601.00 | 626.00 | 811.00 | 1,195.00 | 1,268.00 | 1,966.00 | 1,931.00 | 4,667.00 |
| Borrowings, current | 124.00 | 136.00 | 150.00 | 249.00 | 245.00 | 247.00 | 205.00 | 199.00 |
| Trade payables | 622.00 | 615.00 | 650.00 | 604.00 | 741.00 | 574.00 | 632.00 | 1,032.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 587.00 | 1,085.00 | 535.00 | 1,067.00 | 600.00 | 990.00 | 692.00 | 1,618.00 |
| Net cash from investing activities | -563.00 | -1,174.00 | -667.00 | -1,458.00 | -536.00 | -1,317.00 | -524.00 | -3,653.00 |
| Net cash from financing activities | 98.00 | 88.00 | 87.00 | 488.00 | -60.00 | 532.00 | -211.00 | 2,343.00 |
| Purchase of property, plant and equipment | 460.00 | 522.00 | 394.00 | 971.00 | 553.00 | 1,074.00 | 276.00 | 875.00 |
| Net increase in cash | 121.00 | -4.00 | -45.00 | 97.00 | 4.00 | 205.00 | -42.00 | 313.00 |
| con:CFO.BEFORE_TAX | 633.00 | 1,170.00 | 570.00 | 1,158.00 | 621.00 | 1,116.00 | 772.00 | 1,774.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 46.00 | 86.00 | 35.00 | 91.00 | 21.00 | 126.00 | 79.00 | 156.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 80.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 1.00 | 0.00 | 3.00 | 0.00 | 3.00 | 0.00 | 7.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 243.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,154.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 63.85 | 0.64 | 0.63 | 0.63 | 0.63 |
| Domestic institutions | 14.14 | 11.95 | 10.89 | 10.23 | 9.51 | 8.23 | 7.90 | 8.69 | 8.52 | 8.09 | 0.08 | 0.08 | 0.09 | 0.09 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 5.54 | 0.05 | 0.06 | 0.07 | 0.07 |
| Insurance companies | 2.69 | 2.01 | 1.93 | 1.56 | 1.27 | 0.92 | 2.02 | 2.04 | 1.70 | 1.51 | 0.01 | 0.01 | 0.01 | 0.01 |
| Foreign institutions | 10.36 | 11.11 | 11.60 | 11.51 | 10.91 | 10.01 | 9.68 | 9.44 | 9.66 | 10.46 | 0.10 | 0.11 | 0.10 | 0.09 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 35.52 | 35.52 | 35.53 | 35.53 | 35.53 | 35.53 | 35.53 | 35.53 | 35.53 | 35.53 | 0.36 | 0.36 | 0.36 | 0.36 |
| Non-institutional | 11.01 | 12.46 | 13.05 | 13.79 | 15.11 | 17.29 | 17.95 | 17.40 | 17.35 | 16.98 | 0.17 | 0.17 | 0.17 | 0.18 |
| Shares outstanding | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 | 204360804 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Samyat Health Private Limited | Wholly-owned subsidiary | Any other transaction, Loan, Purchase of goods or se | 1,200,690,000.00 | 8 |
| NH Integrated Care Private Limited | Wholly-owned subsidiary | Any other transaction, Loan, Sale of goods or servic | 405,760,000.00 | 6 |
| Health City Cayman Islands Ltd. | Wholly-owned subsidiary | Any other transaction | 273,640,000.00 | 2 |
| Dr. Devi Prasad Shetty | Chairman and Promoter | Remuneration | 104,800,000.00 | 1 |
| Samyat Healthcare Private Limited | Fellow Subsidiary | Purchase of goods or services, Sale of goods or serv | 92,100,000.00 | 3 |
| Dharamshila Cancer Foundation and Research Centre | Narayana Hrudayalaya Surgical Hosp | Any other transaction, Purchase of goods or services | 78,070,000.00 | 6 |
| Dr. Emmanuel Rupert | Key Managerial Personnel | Any other transaction, Remuneration | 53,930,000.00 | 2 |
| Narayana Hrudayalaya Surgical Hospital Private Limited | Fellow Subsidiary | Sale of fixed assets, Sale of goods or services | 48,350,000.00 | 2 |
| Meridian Medical Research & Hospitals Ltd. | Fellow Subsidiary | Sale of goods or services | 47,350,000.00 | 1 |
| Amaryllis Healthcare Pvt. Ltd | Entity under control / joint contr | Purchase of goods or services | 38,290,000.00 | 1 |
| Narayana Hrudayalaya Surgical Hospitals Private Limited | Wholly-owned subsidiary | Any other transaction, Sale of goods or services | 35,960,000.00 | 2 |
| Amaryllis Healthcare Private Limited | Entity under control / joint contr | Purchase of goods or services | 28,220,000.00 | 4 |
| Viren Shetty | Whole-Time Director | Remuneration | 27,530,000.00 | 1 |
| Meridian Medical Research & Hospital Limited | Subsidiary | Any other transaction, Purchase of goods or services | 14,550,000.00 | 4 |
| Narayana Hrudayalaya Foundations | Trust in which Promoter is a Trust | Any other transaction | 14,460,000.00 | 4 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-10 | Q1FY27 | and Investor Relations., long-term sustainability. | Read the call |
| 2026-06-02 | Q4FY26 | FINANCE AND INVESTOR RELATIONS, INVESTOR RELATIONS | Read the call |
| 2025-02-24 | Q3FY25 | ACQUISITIONS & INVESTOR RELATIONS, MANAGING DIRECTOR, SUBSIDIARY HCCI | Read the call |
| 2024-11-11 | Q2FY25 | MANAGING DIRECTOR, SUBSIDIARY HCCI | Read the call |
| 2024-08-13 | Q1FY25 | MANAGING DIRECTOR, SUBSIDIARY HCCI | Read the call |
| 2024-05-31 | Q4FY24 | MANAGING DIRECTOR, SUBSIDIARY HCCI | Read the call |
| 2024-02-22 | Q3FY24 | MANAGING DIRECTOR, SUBSIDIARY HCCI | Read the call |
| 2023-11-21 | Q2FY24 | MANAGING DIRECTOR | Read the call |
| 2023-08-11 | Q1FY24 | MANAGING DIRECTOR | Read the call |
| 2023-05-29 | Q4FY23 | MANAGING DIRECTOR | Read the call |
| 2023-02-15 | Q3FY23 | MANAGING DIRECTOR | Read the call |
| 2022-11-14 | Q2FY23 | MANAGING DIRECTOR | Read the call |
| 2022-08-16 | Q1FY23 | MANAGING DIRECTOR | Read the call |
| 2022-05-30 | Q4FY22 | MANAGING DIRECTOR | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q2FY25 | Q3FY23 | Q3FY24 | Q3FY25 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | My second question is on your Capex projection for FY25. So, I understand you have earmarked around 9 billion of Capex towards greenfield and inorgani… | I guess in an interview you mentioned that the oncology department will commence from Q1. So, how much is the capex that went for this particular bloc… | And there is one question on the Capex, could you give the timeline for the new hospital in Cayman and then also you know the Greenfield and brownfiel… | So, over the last 5-10 odd years, Narayana was little conservative in terms of adding more beds, doing some sort of brownfield or greenfield Capex in … | First, we will be investing significant capex into our best-performing centers. | Our Industry leading average ROCE of over 28% and our targeted CapEx strategy focusing on judicious allocation of capital continues to deliver sharp r… | Good aŌernoon I was looking for a liƩle more detail on your bed expansion plans especially in the light from your PPT, I can see that the greenfield ca… | We have shared information relating to Eastern Peripheral, and we have shared information relating to our capex and expansion plan for Raipur. |
| Capital allocation | So, why is it that we are not looking at acquisition as an opportunity because you already get a built-up hospital and potentially broke even? | So, as you are aware we recently announced an acquisition of a very niche ENT practice which is one of the highest volume practices in the Island. | So, I think we have moved more towards daycare-oriented procedures especially with an acquisition with it recently and certain change in the approach … | We are not looking to make acquisition of controlling stake in Spire Healthcare. | Myself Debangshu and as most of you are aware, I run the Investor Relations and Mergers & Acquisition practices at NH. | Provided we don't do any more expansion and acquisition and greenfield things. | — | So, the entire acquisition debt is on the books of the target. |
| Costs | — | — | So, what, where is the cost savings coming from? | — | Having said that we've always looked at efficiencies first, when we have cost pressures, we look at internal efficiencies. | So, there is a value proposition, there is a cost saving, but it's a question of communicating it to the person who is able to influence the direction… | The second aspect is that, as you know, we don't pass on the complete cost inflation to price and, therefore, we absorb a lot of our cost inflation wi… | — |
| Debt and cash | So in the next 5-10yrs., what is the difference we can see in our revenues or the working capital when the percentage of insurance increases in our pr… | Our overall balance sheet and liquidity profile remains strong with group cash and liquid investments of over INR 5.6 billion against gross borrowings… | Our net debt- to-equity ratio now stands at -0.01, giving us sufficient room to fund our expansion through a mix of borrowing and internal accruals. | — | — | So, obviously this year the cash flow generation has been very strong. | The balance sheet and liquidity profile at the group level remains strong, with group cash and liquid investments of over INR 12.58 billion against gr… | At the moment, we believe that we have adequate cash flow to pay back the loan. |
| Demand | So, my first question was despite the growing demand for healthcare services in India and the relatively low debt to equity ratios of established hosp… | The reason I asked is given that there is adequate demand next year and thereafter, would your capacity suffice to grow at a double-digit rate? | Even at most of the hospitals are trying to convert general words into semiprivate to meet the demand for insurance and cash payors. | But there are projects in pipeline and we do believe that we will bridge some of it in the current year. | And regarding our numbers in April, we are trending positive, In March, there was a lot of pent-up demand and it was our highest ever number. | But what we're really counting on in the longer term, which is a little much more uncertain, is the demand for radiotherapy services from the broader … | We did have quite a lot of pent-up demand in the post-COVID years and a lot of catch-up growth that's happening. | All our pharmacies are fulfilling internal demand. |
| Guidance | I would also like to remind you that everything that is being said on this call, that reflects any outlook for the future, or which can be construed a… | I would also like to remind you that everything that is being said on this call that reflects any outlook for the future or which can be construed as … | I would also like to remind you that everything that is being said on this call that reflects any outlook for the future or which can be construed as … | We would also like to remind you that everything that is being said on this call that reflects any outlook for the future, or which can be construed a… | I would also like to remind you that everything that is being said on this call that reflects any outlook for the future or which can be construed as … | I would also like to remind you that everything that is being said on this call that reflects any outlook for the future or which can be construed as … | I would also like to remind you that everything that is being said on this call, that reflects any outlook for the future, or which can be construed a… | Yes, we are not giving any guidance, but what we have explained is that the 20% margin, which has come at a consol level has one-timer impact on it be… |
| Margin | Sir, when you say margin dilution for 4-5 quarters, you mean the margins will be less than 40% for four quarters. | Narayana Hrudayalaya generated consolidated EBITDA of INR 2,660 million in Q3 FY23 at a margin of 23.6% against 22.3% of Q2 FY23, when adjusted for th… | The improvement will show over a period of time, but the positive thing is this is reflecting in our improved margin profile despite our difficult qua… | But let's look at Q2, where we had about, I would say, 5% to 7% margin dilution. | On a consolidated basis, we delivered an EBITDA of INR 1,848 mn at margin of 19.6% growing at 23.3% on year-on- year (YoY) basis with PAT of INR 690 m… | NHL generated Consolidated EBITDA of INR 2,904 million in Q4 FY23 at a margin of 23.8% against 23.6% of Q3 FY23. Our Cayman unit continues to contribu… | Narayana Hrudayalaya Limited generated a consolidated EBITDA of INR 3,184 million for Q4 FY 24, at a margin of 24.9%, against 23.8% in Q4 FY 23. | So, the effective dilution is about 300 bps. So normalized margin around 22%. |
| People | But what we want to do is to build up a habit and understand what are the modules that they value the most, so we get a better understanding of their … | And in terms of capacity utilization, where are we currently on the current facility, on the IP side? | So, basically it was just to see how much bed utilization you all are at, because despite your daycare procedures not being counted in that, the bed i… | So, what I wanted to understand is, all the cash proceeds that you get from your Cayman Islands business, what is going to be the utilization of the s… | Because you're saying you're hitting your peak utilization at 50% to 55% occupancy? | And in terms of utilization, you know, obviously this is not going to be like on a bed count basis but any idea you could give us as to what sort of a… | So, for that, we would be hiring people to match up to the same. | No, there is no movement in the total headcount, but the booking in Q3 was slightly on the higher side in percentage terms vis-a-vis revenue. |
| Pricing | See, our typical price increase is low single digits, 4-5% every year. | To that extent pricing will not drive ARPOB, ARPOB will come because of mix of great going to higher quaternary procedures, as well as improvement on … | — | Sandhya, any extra things you want to add on that, on pricing and so on? | The pricing is a lot higher, and the realization per patient is a lot higher given that these are in very key markets. | So, could you provide the breakup in terms of price hike and peer and specialty mix? | Yeah, as far as the pricing goes, wherever it is predictable clinical pathways, we prefer to have package the procedure so that the patient knows that… | But the one thing to note is that year-on- year, the rack rate and the price increases that we take hover in the low to mid-single digits. |
| Revenue growth | It's given a very strong revenue growth around 13% year-on-year, with the revenue crossing around ₹130 crores for this quarter, with an EBITDA of arou… | Consolidated revenue for the quarter stood at INR 11,282 million reflecting a Year-on-Year growth of 17.5%, and a marginal decline of 1.2% compared to… | Consolidated revenue for the current quarter stood at INR 12,036 million reflecting a growth of 6.7% year-on-year and - 7.8% quarter-on-quarter. | So, we're very happy to see that a lot of that was covered because of the revenue growth. | What we have been trying here and there are these little efficiencies that you can get by moving to online appointments by reconfiguring the bed mix by m… | Consolidated revenue for the current quarter stood at INR 12,216 million reflecting a year-on-year growth of 29.9% resulting in a consolidated fiscal … | Consolidated revenue for the current quarter stood at INR 12,794 million, reflecting a growth of 4.7% year-on-year and 6.3% quarter-on-quarter. | So you have to assume that a similar run rate of cash burn will continue on the clinics going into next year as well because we still have a significa… |